Journal
CANCER LETTERS
Volume 334, Issue 2, Pages 253-262Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.08.009
Keywords
Paclitaxel; 2 '-Behenoyl-paclitaxel; Nanoparticle; 4T1 mouse model; Metastatic breast cancer
Categories
Funding
- NIH-NCI [R01 CA115197, U54 CA151652]
Ask authors/readers for more resources
The aim of these studies was to develop a novel 2'-behenoyl-paclitaxel (C22-PX) conjugate nanoparticle (NP) formulation for the treatment of metastatic breast cancer. A lipophilic paditaxel derivative C22-PX was synthesized and incorporated into lipid-based NPs. Free C22-PX and its NP formulation were evaluated in a series of in vitro and in vivo studies. The results demonstrated that C22-PX NPs were much better tolerated and had significantly higher plasma and tumor AUCs compared to Taxol at the maximum tolerated dose (MTD) in a subcutaneous 4T1 mouse mammary carcinoma model. These benefits resulted in significantly improved antitumor efficacy with the NP-based formulation. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available